Skip to main content
Log in

Preclinical target validation using patient-derived cells

  • Comment
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

Abstract

The Structural Genomics Consortium (SGC) and its clinical, industry and disease-foundation partners are launching open-source preclinical translational medicine studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Bunnage, M. E. Getting pharmaceutical R&D back on target. Nature Chem. Biol. 7, 335–339 (2011).

    Article  CAS  Google Scholar 

  2. Marshall, J. C. Why have clinical trials in sepsis failed? Trends Mol. Med. 20, 195–203 (2014).

    Article  Google Scholar 

  3. Brennan, F. M. et al. Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2, 244–247 (1989).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael Sundström.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Edwards, A., Arrowsmith, C., Bountra, C. et al. Preclinical target validation using patient-derived cells. Nat Rev Drug Discov 14, 149–150 (2015). https://doi.org/10.1038/nrd4565

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4565

  • Springer Nature Limited

This article is cited by

Navigation